Abstract
765P SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have